N.Yu. KRUTIKOVA¹, A.S. EFREMENKOVA^1, 2

 ¹Smolensk State Medical University, Smolensk

²Children’s Clinical Hospital № 3, Smolensk

 Contact details:

Krutikova N.Yu. — MD, Associate Professor of the Department of Outpatient Pediatrics

Address: 22a Tvardovsky St., Russian Federation, Smolensk, 214019, tel.: +7-915-655-22-60, e-mail: krutnad@mail.ru

 At present, it has been proved that adipose tissue, in addition to storing energy, is a complex hormonally active organ. Biological active substances secreted by adipose tissue, entering the general circulation, have a variety of metabolic effects, interact with various organs and systems, in particular with bone tissue, and participate in maintaining the constancy of the body internal environment. A number of hormones secreted by adipose tissue are well studied, such as leptin, adiponectin, interleukin-6, etc., others require further research in order to study their effects on various organs and systems. The published data suggest the multidirectional effect of biologically active substances on bone metabolism. The biological activity of hormones can be increased or decreased when interacting with receptors and/or binding proteins. Lack or excess of adipose tissue leads to various metabolic disorders and a shift in the dynamic balance of the constancy of the internal environment of the body.

Key words: obesity, osteoblasts, osteoclasts, hormone, adipose tissue, bone metabolism.

REFERENCES

1. The global burden of disease: generating evidence, guiding policy – European Union and European Free Trade Association regional edition. Seattle (WA): Institute for Health Metrics and Evaluation, 2013, 4 (http://www.healthmetricsandevaluation.org/sites/default/files/policy_report.pdf, accessed on: 4 December 2013)
2. Kiess W., Penke M., Sergeyev E., Neef M., Adler M., Gausche R. et al. Childhood obesity at the crossroads. J. of Pediatric Endocrinol. and Metabol, 2015, vol. 25, pp. 312–330.
3. Afanas’ev Yu.I., Yurina N.A., Kotovskiy E.F. et al. Gistologiya, tsitologiya, embriologiya: uchebnik [Histology, cytology, embryology: textbook]. Moscow: Meditsina, 2012. 800 p.
4. Rosen E.D., Spiegelman B.M. Molecular regulation of adipogenesis. Ann. Rev. Dev. Biol., 2000, vol.16, pp. 145–171.
5. Sekiya I., Larson B.L., Smith J.R., Pochampally R., Cui J.G., Prockop D.J. Expansion of human adult stem cells from bone marrow stroma: conditions that maximize the yields of early progenitors and evaluate their quality. Stem Cells, 2002, vol. 20 (6), pp. 530–541.
6. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metabol, 2004, vol. 89, pp. 2548–2556.
7. Reid I.R. Relationships among body mass, its components, and bone. Bone, 2002, vol. 31, pp. 547–555.
8. Muhlen D., Safii S., Jassal S.K., Barret-Connor E. Associations between the metabolic syndrome and bone health in older men and women: the Rancho Bernando Study. Osteoporos Int, 2007, vol. 18 (10), pp. 1337–1344.
9. Yaturu S., Humphrey S., Landry C., Jain S.K. Decreased bone mineral density in men with metabolic syndrome alone and with type 2 diabetes. Med Sci Monit, 2009, vol. 15 (1), pp. 5–9.
10. Premaor M.O., Pilbrow L., Tonkin C.J., Parker R.M., Compston J. Obesity and fractures in postmenopausal women. J Bone and Mineral Research, 2010, vol. 25 (2), pp. 292–297.
11. Sekiya I., Larson B.L., Smith J.R., Pochampally R., Cuib J.G., Prockop D.J. Expansion of human adult stem cells from bone marrow stroma: conditions that maximize the yields of early progenitors and evaluate their quality. Stem Cells, 2002, vol. 20 (6), pp. 530–541.
12. Rodríguez J.P., Montecinos L., Ríos S., Reyes P., Martínez J. Mesenchymal stem cells from osteoporotic patients produce a type I collagen-deficient extracellular matrix favoring adipogenic differentiation. J Cell Biochem, 2000, vol. 79 (4), rr. 557–565.
13. Arai F., Miyamoto T., Ohneda O., Inada T., Sudo T., Brasel K. et al. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med, 1999, vol. 190, pp. 1741–1754.
14. Boyce B.F., Li P., Yao Z. TNF-α and pathologic bone resorption. The Keio Journal of Medicine, 2005, vol. 54 (3), pp. 127–131.
15. Sardar S., Reeby T., Puthiyaveetil S., Devarajan S., Kazem B., Rasheed A. Obesity is a positive modulator of IL-6R and IL-6 expression in the subcutaneous adipose tissue: significance for metabolic inflammation. PLoS ONE, vol. 10 (7), pp. e0133494.
16. Luo X.H., Guo L.J., Yuan L.Q., Xie H., Zhou H., Wu X.P. et al. Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res, 2005, vol. 309 (1), pp. 99–105.
17. Luo X.H., Guo L.J., Xie H., Yuan L.Q., Wu X.P., Zhou H.D. et al. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res, 2006, vol. 21 (10), pp. 1648–1656.
18. Margetic S., Gazzola C., Pegg G.G., Hill R.A. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord, 2002, vol. 26 (11), pp. 1407–1433.
19. Benomar Y., Wetzler S., Larue-Achagiotis C., Djiane J., Tome D., Taouis M. In vivo leptin infusion impairs insulin and leptinsignalling in liver and hypothalamus. Mol. Cell. Endocrinol, 2005, vol. 242, pp. 59–66.
20. Chigar’kova O.V., Butrova S.A., Nikankina L.V., Lyul’eva E.G., Mel’nichenko G.A. Leptin and indicators of the state of bone tissue in obese postmenopausal women. Ozhirenie i metabolizm, 2005, vol. 2, no. 3, pp. 29–32 (in Russ.).
21. Martini G., Valenti R., Giovani S., Franci B., Campagna S., Nuti R. Influence of insulin-like growth factor-1 and leptin on bone mass in healthy postmenopausal women. Bone, 2001, vol. 28 (1), pp. 113–117.
22. Goulding A., Taylor R.W. Plasma leptin values in relation to bone massand density and to dynamic biochemical markers of bone resorption and formation in postmenopausal women. Calcified Tissue Int, 1998, vol. 63 (6), pp. 456-458.
23. Russell T.T., Satya P.K., Carmen P.W., Kenneth A.P., Laurence B.L., Stephane B. et al. Peripheral leptin regulates bone formation. J Bone Mineral Res, 2013, vol. 28 (1), pp. 22–34.
24. Whitfield J.F., Morley P., Willick G.E. The control of bone growth by parathyroid hormone, leptin, & statins. Crit Rev Eukaryot Gene Expr, 2002, vol. 12 (1), pp. 23–51.
25. Fisher A., Southcott E., Li R. Serum resistin in older patients with hip fracture: Relationship with comorbidity and biochemical determinants of bone metabolism. Cytokine, 2011, vol. 56 (2), pp. 157–166.
26. Costa D., Lazzarini E., Canciani B. Altered bone development and turnover in transgenic mice overexpressing lipocalin-2 in bone. J Cell Physiol, 2013, vol. 228 (11), pp. 2210–2221.
27. Fukuhara A., Matsuda M., Nishizawa M. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science, 2005, vol. 307 (5708), pp. 426–430.
28. Moschen A.R., Kaser A., Enrich B. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J. Immunol, 2007, vol. 178 (3), pp. 1748–1758.
29. Venkateshaiah S.U., Khan S., Ling W. NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity. Exp. Hematol, 2013, vol. 41 (6), pp. 547–557.
30. Iacobellis G., Iorio M., Napoli N. Relation of adiponectin, visfatin and bone mineral density in patients with metabolic syndrome. J Endocrinol Invest, 2011, vol. 34 (1), pp. 12–15.
31. Kamio N., Kawato T., Tanabe N. Vaspin attenuates RANKL-induced osteoclast formation in RAW264.7 cells. Connect. Tissue Res, 2013, vol. 5 (2), pp. 47–52.
32. Xie H., Yuan L.Q., Luo X.H., Huang J., Cui R.R., Guo L.J. et al. Apelin suppresses apoptosis of human osteoblasts. Apoptosis, 2007, vol. 12, pp. 247–254.
33. Zhang H., Xie H., Zhao Q. Relationships between serum adiponectin, apelin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in post-menopausal Chinese women. J. Endocrinol. Invest, 2010, vol. 33 (10), pp. 707–711.